Rising Geriatric Population Coupled with Pericardial Diseases Anticipated to Foster the Market Growth

Published: Jun 2021

The global pericardial disease market is anticipated to grow at a CAGR of around 5.5% during the forecast period (2021-2027). The factors attributing to the growth of the market include the growing geriatric population and rising prevalence of the pericardial disease across the globe. According to United Nations, Department of Economic and Social Affairs report for World Population Ageing 2019, by 2050, 1 in 6 people in the world will be over the age of 65, up from 1 in 11 in 2019. In line with this, there were 703 million persons aged 65 years or over in the world in 2019. The number of older persons is projected to double to 1.5 billion in 2050. Globally, the share of the population aged 65 years or over increased from 6.0% in 1990 to 9.0% in 2019. That proportion is projected to rise further to 16.0% by 2050, so that one in six people in the world will be aged 65 years or over. Though, geriatric populations are more vulnerable to pericardial disease creates demands for advanced treatments, thus higher growth in the market can be seen in upcoming years. Moreover, the rising cardiac diseases are expected to increase the sales for the drugs and treatments associated with the diseases. 

Browse the full report description of "Global Pericardial Disease Market Size, Share & Trends Analysis Report By Type (Acute Pericarditis, Chronic Pericarditis, and Recurrent Pericarditis) By Diagnosis Method (Chest X-Ray, Cardiac MRI, Cardiac CT Scan, Echocardiography, Electrocardiography, and Others) By Treatment Approach (NSAIDS Drugs, and Pericardiectomy) Forecast 2021-2027" at https://www.omrglobal.com/industry-reports/pericardial-disease-market

By geography, Eastern and South-Eastern Asia and Latin America and the Caribbean are the regions with a higher % of the aged population. In Eastern and South-Eastern Asia, the aged population has increased from 6% in 1990 to 11% in 2019, and from 5% to 9% in Latin America and the Caribbean in respective years. Moreover, the developments in the treatments and FDA approvals to the drugs launched by the market players can be expected to further increase the global pericardial diseases market growth. 

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered- 

o By Application

o By Function

  • Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

  • Competitive Landscape- Teva Pharmaceutical Industries Ltd., AstraZeneca PLC, Abbott Laboratories, Edwards Lifesciences Corp, Integra LifeSciences Corp, among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Pericardial Disease Market Report Segment

By Type

  • Acute Pericarditis
  • Chronic Pericarditis
  • Recurrent Pericarditis

By Diagnosis Method

  • Chest X-Ray
  • Cardiac MRI
  • Cardiac CT Scan
  • Echocardiography
  • Electrocardiography (EKG)
  • Others (Blood Test)

By Treatment Approach

  • Nonsteroidal Anti-Inflammatory Agents (NSAIDS) Drugs
  • Pericardiectomy

Global Pericardial Disease Market Report Segment by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Russia 
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World

  • Latin America 
  • Middle East & Africa

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/pericardial-disease-market